hydroxychloroquine and Embryopathies

hydroxychloroquine has been researched along with Embryopathies in 4 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Abnormal Fluid Collection

(NCT01379573)
Timeframe: At birth (approximately 9 months)

Any Sign of Myocardial Injury, Without Change in Cardiac Rate or Rhythm

a) shortening fraction <28% = 2 SD below normal mean or qualitatively reduced systolic function; b) cardio-thoracic ratio >0.33; c) hydropic changes; d) moderate/severe tricuspid regurgitation. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

Birth Weight <10% in the Context of Gestational Age

(NCT01379573)
Timeframe: At birth (approximately 9 months)

Cutaneous Neonatal Lupus

(NCT01379573)
Timeframe: Up to 15 months (at birth - 9 months, and 6 months thereafter)

Echocardiographic Densities Consistent With EFE Confirmed Postnatally

(see title) (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

Fetal Death Not Related to Cardiac Dysfunction

"An autopsy with full evaluation of the heart will be encouraged but cannot be mandated. If AV block or evidence of a cardiomyopathy can be proven, then these will provide the basis for final categorization. If not possible, the death will not be considered a recurrence rate but will be reported." (NCT01379573)
Timeframe: Up to 9 months

Prematurity

(gestational age <37 weeks at birth) (NCT01379573)
Timeframe: At birth (approximately 9 months)

Prolonged PR Interval (>150msec)

EKG at birth must confirm 1st degree AV block. It is also possible that a fetus developing 1st degree block on study medication might have developed more advanced block in the absence of study medication. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

Recurrence of Advanced Heart Block

Echocardiogram reveals 2nd or 3rd degree AV block (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

Reviews

2 reviews available for hydroxychloroquine and Embryopathies

Trials

1 trial available for hydroxychloroquine and Embryopathies

Other Studies

1 other study available for hydroxychloroquine and Embryopathies